BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21477298)

  • 1. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.
    Westwood M; Bourbeau J; Jones PW; Cerulli A; Capkun-Niggli G; Worthy G
    Respir Res; 2011 Apr; 12(1):40. PubMed ID: 21477298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.
    Donohue JF; Jones PW; Bartels C; Marvel J; D'Andrea P; Banerji D; Morris DG; Patalano F; Fogel R
    Pulm Pharmacol Ther; 2018 Apr; 49():11-19. PubMed ID: 29277690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
    Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
    Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
    Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV
    Kang J; Lee JS; Lee SW; Lee JB; Oh YM
    Respir Res; 2021 Feb; 22(1):55. PubMed ID: 33579288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
    Kew KM; Dias S; Cates CJ
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
    Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
    BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
    Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
    Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.
    Martin AL; Marvel J; Fahrbach K; Cadarette SM; Wilcox TK; Donohue JF
    Respir Res; 2016 Apr; 17():40. PubMed ID: 27084761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH; Tan DJ; Walters JA; Walters EH
    Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
    Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis.
    Punekar YS; Sharma S; Pahwa A; Takyar J; Naya I; Jones PW
    Respir Res; 2017 May; 18(1):86. PubMed ID: 28482883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
    Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD
    Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
    Buhl R; de la Hoz A; Xue W; Singh D; Ferguson GT
    Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
    Ohar JA; Bowling A; Goodin T; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():461-470. PubMed ID: 30863047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV
    Chai CS; Ng DL; Bt Mos S; Ibrahim MAB; Tan SB; Pang YK; Liam CK
    BMC Pulm Med; 2023 Apr; 23(1):150. PubMed ID: 37118725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
    Manoharan A; Morrison AE; Lipworth BJ
    Lung; 2016 Apr; 194(2):259-66. PubMed ID: 26758884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.